Introduction
Birthweight is an indicator of the fetal growth, a predictor for neonatal morbidity and is known to be related to the risk of various adulthood pathologic conditions such as cancer, Type 1 and 2 diabetes mellitus (Frayling and Hattersley, 2001; McCormack et al., 2005; Ahlgren et al., 2007) , asthma (Kumar, 2008) , hypertension (Salgado et al., 2009) and coronary heart disease (Leon et al., 1998) . Several epidemiological studies showed that genetic factors account for 30-70% of birthweight variance, whereas environmental factors account only for about 25% (Little and Sing, 1987; Dunger et al., 2007) . The variability of fetal growth is suggested to be genetically multifactorial and hence associated with an interaction of unknown genetic markers (Isles and Holland, 2005) , and few studies have identified specific loci responsible for birthweight. Recent data have revealed that major histocompatibility complex (MHC) molecules play an important role in controlling both implantation and fetal development (Choudhury and Knapp, 2001; Golos, 2004) , and genome-wide scan linkage studies identified 'birthweight associated loci' on chromosome 6 and 7, and a 'ponderal body index (weight/height 3 ) related locus' in the chromosome 6q21 region, at which MHC genes are located (Arya et al., 2006; Fradin et al., 2006) . The human leukocyte antigens (HLAs) are a class of MHC molecules that play important roles in immune response as antigen-presenting molecules and ligands. The extensive polymorphic nature of HLAs results in differences of immune responsiveness among individuals and different ethnic groups (Hill, 1998; Carrington et al., 1999) .The association of HLA genotype with birthweight has mainly been evaluated in diabetes mellitus (DM) patients or families, and only a few reports limited to Caucasians revealed that certain HLA genotypes are associated with the birthweight of healthy neonates (Stene et al., 2001; Larsson et al., 2005; Hummel et al., 2007) ; the association in other populations has not been published to our knowledge. The content (number) of CD34 + cells, which is commonly used as a marker of hematopoietic progenitor cells (HPCs) , is an essential parameter in hematopoietic stem cell transplant sources such as cord blood (CB), and the HPC content of CB has been suggested to reflect and/or affect intrauterine fetal growth and development (Aroviita et al., 2004b; Solves et al., 2005) . Although various factors such as maternal age, gestational age, fetal distress and collection method have been found to be related to cord blood CD34 + cell content (Solves et al., 2005; Jan et al., 2008; Omori et al., 2008) , there is little published data about the association of HLA with this parameter (Aroviita et al., 2004b) . The object of this study was to define HLA genotypes that are associated with normal fetal growth and development in healthy Korean full-term newborns.
To evaluate the association, we analyzed the HLA-A, -B and -DRB1 allele polymorphisms, birthweight and stem cell content of CB using the latter two factors as surrogate markers for fetal growth, in Korean neonates who donated CB to the Seoul Metropolitan Public Cord Blood Bank, Allcord.
Materials and Methods

Subjects
Cord blood units (CBUs) were eligible for cryopreservation if they met certain criteria relating to cell content [collection volume ≥60 ml, total nucleated cell (TNC) count of post-processing product ≥5 × 10 8 ], cell viability (≥80%), sterility, serologic test for infectious disease and medical history related to pregnancy or transferrable disease. With these criteria, 46.0% of total collections (1762/3830 units) were cryopreserved and HLA assigned for HSCT from July 2007 to December 2007. The main reasons for sample discard were insufficient volume or low TNC count (81.8%, 1691/2068), and about 18.0% of CBUs were excluded for failed sterility testing, positive infectious disease screening test or suspicious medical history. Pre-term neonates (,36 gestational weeks) and pathological pregnancies were excluded from CB donation. Among the preserved 1762 units, we analyzed 1628 CBUs from Korean neonates (both parents of which are Koreans) with reliable delivery information and newborn characteristics ( Table I) .
All of the CBUs were voluntarily donated from adult women with informed consent and who completed self-administered medical questionnaires, and the delivery records were provided by the obstetricians. The written consent, medical questionnaires and the study procedures were approved by the Institutional Review Board of Seoul National University Boramae Hospital.
CB collection: pre-placental delivery (in utero) collection It is accepted that delivery practice should not be modified in an attempt to increase CBU volume, and the collection should only occur in uncomplicated delivery by the obstetrician responsible for the delivery. After delivery of the infant, the umbilical cord was clamped immediately and cleaned with 70% alcohol and iodine. CB was collected from the umbilical vein by gravity in a closed sterile 200 ml collection bag containing CPDA-1 anticoagulant (24.5 ml). After collection, CBU was transferred to the cord blood bank in a shipping container that maintained a designated temperature range (room temperature) to protect cell viability during transport.
Processing: red blood cell and plasma depletion and cryopreservation
Within 36 h of collection, CBUs of at least 60 ml with 6 × 10 8 TNCs were processed to reduce volume; samples containing more than 5 × 10 8
TNCs post-processing were required to accept CBUs for preservation. RBC and plasma depletion was performed with hydroxyethylstarch (HES) and centrifugation, and then cryoprotectant (10% DMSO, 5 ml) was added to the concentrated CB (20 ml) before controlled rate freezing.
Data collection and birthweight centile partitioning
We obtained the perinatal information including birthweight, delivery method and pregnancy-related problems from the records of obstetricians. To minimize any confounding factors that may affect fetal growth other than HLA, we reviewed the documents from the obstetricians and medical questionnaires answered by donors, and checked the current and past medical history of the donor and the donor's family, chronic illness, medication, alcohol intake and smoking and gestational DM or overt DM of mother, gestational age and medical problems of neonates. Birthweight was subdivided following the birthweight distribution data of Korean neonates (Lee et al., 2005a) , and the 1628 neonates were divided into six groups according to birthweight centiles. 
Testing of CBUs: analysis of sample quality
Pre-processing CBU volume, pre-and post-processing TNC counts, percent cell viability and post-processing CD34 + cell counts were assessed for each sample. TNC was measured by a XE-2100 hematologic analyzer (Sysmex, Kobe, Japan), and the cell viability was tested by trypan blue staining. The CD34 + cell enumeration was performed by flow-cytometry FACSAria (Becton Dickinson, San Jose, CA, USA) with anti-CD45 FITC and anti-CD34 PE, based on the International Society of Hematotherapy and Graft Engineering (ISHAGE) protocol (Sutherland et al., 1996) .
Testing of CBUs: analysis of sterility and infectious disease
Sterility tests (aerobic and anaerobic culture) were performed with a microbial detection system (BacT/ALERT, bioMérieux, Inc., Durham, NC, USA) on samples of leukocyte-poor plasma incubated for 5 days, and non-sterile CBUs were discarded. Serologic screening for infectious disease was performed by assessing anti-CMV IgG/M, HBsAg, syphilis, anti-HCV, anti-HIV-1/2 in maternal and CB plasma samples. CBUs with positive hepatitis B, C or HIV tests were discarded. However, CBUs with positive syphilis screening results but a negative confirmatory test were not excluded, in accordance with the standard guidelines for blood donors from 'Korea Center of Disease control and Prevention'. CBUs from infants or mothers with anti-CMV IgM positive results were further tested for CMV DNA using the PCR-restriction fragment length polymorphism (RFLP) method.
DNA-based HLA typing and antigen assignment
HLA type, the final and most expensive test, was assigned only for eligible CBUs after review of records and test results. Genomic DNA was prepared from anticoagulant-treated CB using the Puregene w DNA purification kit (Gentra Systems, Minneapolis, MN, USA). Each sample was initially typed for HLA-A, -B and -DRB1 alleles at low to intermediate resolution by polymerase chain reaction using sequence-specific oligonucleotide probes (PCR-SSOP) with Dynal RELI w SSO typing kits (Invitrogen, Bromborough, Wirral, UK) following the manufacturer's protocols. For samples with ambiguous results, additional typing was performed using PCR-sequence specific primers (PCR-SSP) or by the sequence-based typing (SBT) method. Following the recommendation of the 'Korea marrow donor program (KMDP)', 2-digit level DNA typing results were converted to serologic equivalents, especially for the HLA-B alleles. For example, B*1501/28/38, B*4002/3 typing result was assigned as B*15 (62), B*40 (61). The assignment of serologic equivalents was performed according to the World Health Organization HLA nomenclature (Marsh et al., 2005) and the IMGT/HLA database (http://www.ebi.ac.uk/imgt/hla, accessed Dec 21, 2009).
Statistical analysis
Allele frequencies of HLA-A, -B and -DRB1 were calculated by direct counting and deviations from the Hardy -Weinberg equilibrium (HWE) were evaluated by the exact test of Guo and Thompson (Guo and Thompson, 1992 Results from the study of 1600 Korean marrow donors (healthy adults); ‡ Alleles observed with less than 0.05% frequency. CBU, cord blood unit. the x 2 test or two-tailed Fisher's exact test, as appropriately. The level of significance was set at P , 0.05, and where indicated as corrected P (P c ), a Bonferroni correction was applied by multiplying the probability value by the number of alleles compared (e.g. 13, 30 and 13 for A, B and DRB1 loci, respectively) to control for overall type I error (Bland and Altman, 1995) .
Results
Descriptive statistics of CBUs and donors
We listed the perinatal characteristics of the 1628 newborns and pre-/post-processing laboratory parameters of CBUs in Table II . As pregnancies with complications were excluded from CB donation, neither neonates nor their mothers had major medical issues such as pregnancy-related problems and gestational/overt DM. In accordance with the banking criteria, all of the cryopreserved CBUs were collected after vaginal delivery or Caesarean section without complication from healthy full-term neonates (≥37 weeks of gestational age) and ≥18-year-old mothers. Maternal age and gestational age fell into a normal distribution, as did the birthweight centile considering gestational age. A total of 13 HLA-A, 30 HLA-B and 13 HLA-DRB1 alleles were identified at serologic equivalents and the overall distribution of genotypes at each locus did not show any significant deviations from the HWE proportions, with P-values of 0.48, 0.51 and 0.06 for A, B and DRB1 alleles, respectively. We compared the allele frequencies with those of normal healthy 1600 Korean adults (Roh et al., 2003) , and did not detect a significant difference (Table III) .
Birthweight versus HLA genotype
We investigated the trend of birthweight according to the presence of specific alleles using crosstabulation. The HLA-A*24 allele showed a decreasing trend, with a higher phenotypic frequency in the lower birthweight centile group than the higher birthweight centile group (P ¼ 0.01; Fig. 1A) . All of the HLA-B*47 positive neonates (n ¼ 2) were in the .75th birthweight centile group, following a positive trend (P ¼ 0.042). There was a marginally significant increasing trend of HLA-DRB1*04 frequency related to the increase of birthweight centile (P ¼ 0.058; Fig. 2A ). Comparing heterozygous and homozygous subjects, HLA-A*24 homozygotes were more frequent in the lower birthweight group although HLA-DRB1*04 homozygotes were more frequent in the higher birthweight centile, a statistically significant difference (P ¼ 0.018, 0.047; Figs 1B and 2B ). There was a significant association between birthweight not adjusted by gestational age and both the HLA-A*31 and B*58 alleles. However, HLA-A*31 positive neonates weighed more at birth whereas B*58 positive neonates weighed less (P ¼ 0.041, 0.043). We also compared the frequency of HLA allele phenotypes in the lowest birthweight group (,10th centile) with those in the highest group (.90th centile), and found that the A*03 and A*24 alleles were significantly more frequent in the lowest birthweight subgroup (A*03, 11.1% versus 3.6%, P ¼ 0.034; A*24, 52.8% versus 31.7%, P ¼ 0.002, P c ¼ 0.026). B*52 frequency was similarly elevated in this group, with borderline significance (6.9% versus 1.8%, P ¼ 0.056). Among these candidate alleles, the frequency of A*24 was significantly different between the extreme birthweight groups after Bonferroni correction. The significance was consistent in subjects lacking the B*52 allele, another candidate allele that showed strong linkage disequilibrium with A*24. The associations of birthweight with HLA alleles are listed in Table IV .
Hematopoietic stem cell content versus HLA genotype
The mean percentage of CD34 + cells out of TNC was significantly different among birthweight centile groups, with a positive correlation between birthweight and CD34 + cell percentage (P , 0.001; Fig. 3 ). in the absence of B*07 and B*52 alleles, which showed strong linkage disequilibrium with A*24. DRB1*03 showed significant association with CD34 + cell content after Bonferroni correction. The association of CB stem cell contents with HLA genotype is listed in Table V .
Discussion
Genetic factors determining fetal growth have previously been studied (Demerath et al., 2007; Dunger et al., 2007; Basso, 2008) , but association studies on HLA and birthweight have focused primarily on type I DM (Larsson et al., 2005; Hummel et al., 2007; Pettitt and Jovanovic, 2007) , and only a few studies have reported an association between birthweight and cord blood HPC with HLA (Aroviita et al., 2004a; Capittini et al., 2009) . In this study, HLA allelic (phenotype) frequencies were analyzed in 1628 Korean full-term neonates with respect to birthweight and cord blood HPC content. When compared with the HLA distribution of Korean healthy adults, the HLA distribution in the preserved CBUs that met the inclusion criteria was found to be representative of the normal population data. Among the alleles that we found to be associated with birthweight, the HLA-A*24 and DRB1*04 alleles have been reported to be associated with insulin dependent diabetes mellitus (Nakanishi et al., 1999; Larsson et al., 2005; Hummel et al.2007) . A number of studies in various populations revealed that the influence of DRB1*04 allele on birthweight and/or DM is probably consistent across different populations (Jarvinen et al., 2008) . We found that the frequency of HLA-A*24 or DRB1*04 homozygotes (A*24/A*24 or DRB1*04/DRB1*04) were higher than those of heterozygotes (A*24/A*non-24, DRB1*04/DRB1*non-04) or negative (A* non-24/ A*non-24, DRB1* non-04/DRB1*non-04) in the 'large for gestational age' subjects independent of DM, which suggests that HLA-A*24, DRB1*04 alleles have a strong association with birthweight. However, the present findings do not exclude the possibility that other HLA loci within a conserved extended haplotype containing the HLA-A*24 or DRB1*04 allele or MHC/non-MHC genes tightly linked with these alleles may contribute to fetal growth. Both CD34 + cell concentration (per ml) and relative CD34 + cell content (CD34 + cells/TNC, %) showed negative correlation with HLA-A*24, A*30, B*07, B*52, B*58 and DRB1*03 alleles, and HLA-A*24 and B*52 were also associated with lower gestational birthweight. We have also found a positive correlation between CD34 + cell content and birthweight, in accordance with several other studies, suggesting that HPC content reflects or affects fetal growth and development (Aroviita et al., 2004a, b; Solves et al., 2005) .
Among the alleles that we found the association with birthweight and/or CD34 + cell content, a strong linkage disequilibrium of A*24-B*07, A*24-*B52, B*58-DRB1*03 have been reported in Koreans (Park et al., 1998; Lee et al., 2005a, b) , and the majority of B*07 or B*52 possessing neonates identified in this study also carry A*24 (102/143 and 73/77, respectively). We found that A*24 is associated with birthweight and/or CD34 + cell content regardless of the associated B allele; however, the association of B*07 and B*52 with birthweight and/or CD34 + cell content is inconclusive because there is a scarcity of A*24(2) B*52(+) and A*24(2) B*07(+) subjects. HLA-B*58 and DRB1*03 showed positive correlation with birthweight and/or CD34 + cell content, but the association of B*58 with CD34 + cell content disappeared in the DRB1*03-negative neonates, and also in DRB1*03(+) B*58(2) neonates. This suggests that both DRB1*03 and B*58 alleles might play roles in establishing the CD34 + content of fetus (cord blood), but it is not clear which allele has a more dominant affect on CD34 + content. In addition, we should evaluate A-Cw and Cw-B haplotypes with strong linkage disequilibrium in Koreans, because fetal HLA-C2 genotype (Cw2, Cw4, Cw5, Cw6, Cw15, Cw1602, Cw17, Cw18) is well-known to be associated with pregnancy outcome such as poor trophoblast invasion, pre-eclampsia and recurrent miscarriage (Hiby et al., 2004 (Hiby et al., , 2008 . According to the results of previous Korean studies, HLA-C2 genotype comprise 12-17% and HLA-A, -B alleles showing strong linkage disequilibrium with C2 genotype are A*01, A*11, A*30, B*13, B*15 (B62), B*37, B*44 and B*57 (Park et al., 1998; Lee et al., 2005a, b) . Among the HLA-A and -B alleles that showed association with birthweight and/or CD34 + cell content in this study, none exhibited a strong linkage disequilibrium (x 2 . 10.8)
with HLA-C2 genotype except the A*30 allele. Considering the linkage disequilibrium between the HLA loci and multiple allele comparison, A*24 and DRB1*03 alleles might be significantly associated with fetal growth restriction in late pregnancy.
We have attempted to minimize potential confounding factors by adjusting for factors known to affect intrauterine fetal growth such as maternal DM, smoking, alcohol intake, drug, medical condition, congenital anomaly of neonates; however, we cannot exclude the effects of maternal nutritional status or obesity on birthweight and/or stem cell content. The strong association between birthweight and HLA-DRB1*13 found in Finnish newborns (Aroviita et al., 2004a) , and the HLA haplotypes related with birthweight (A*02-B*15, B*38-DRB1*13, A*01-B*08-DRB1*03, A*30-B*13-DRB1*11) identified in Italian cord blood donors (Capittini et al., 2009) were not found in this study. The results presented here differ from the Caucasian studies in that all of the candidate genotypes (A*01, A*02, A*30, B*08, B*15, B*13, B*38, DRB1*03, DRB1*11, DRB1*13) did not show an association with birthweight in Korean full-term neonates, except A*30 and DRB1*03, which were related to the CD34 + cell content. Since the allele and haplotype frequencies of HLA differ among various populations and linkage disequilibrium patterns tend to be unique in each ethnic group (Imanishi et al., 1992; Cao et al., 2001) , some alleles that are highly associated with fetal size and HPC that are relatively uncommon in Korean, such as HLA-B*38 and B*01, may be mistakenly considered neutral in population association studies. In the same context, differences in distribution of HLA-A*24 among populations could potentially result in an underestimation of its effect in Caucasians. HLA-A*24 is a very common allele in Asian populations, including Korean (.20%), and relatively less frequent in Caucasians (7 -10%) (Gjertson et al., 1998; Park et al., 1998; Lee et al., 2005a, b) . The predominant HLA-A*24 (serologic equivalent A24) allele in Korean is HLA-A*2402 (Lee et al., 2005a, b) , which in contrast comprises a small and variable portion ranging from 0.1 to 10% in Caucasians (Gjertson et al., 1998) . In addition, a significant P-value for rare alleles such as HLA-B*47 (P ¼ 0.042, phenotype frequency of 0.001) could be obtained by chance and should be analyzed using larger scale samples to confirm the significance. Further study should be conducted with subject groups large enough to classify subgroups according to A*24, B*07, B*52, B*58 and DRB1*03 positivity in order to clarify these associations. Likewise, extending the analyses to preterm babies ,36 weeks, which were excluded in this study, will be helpful in investigating the association of fetal growth with HLA throughout the entire pregnancy period. Moreover, studies in other populations are necessary to comprehensively understand the genetic factors that contribute to birth size, and to define different and common genetic factors among ethnicities. Clearly revealing an association between birthweight and stem cell content with a specific HLA genotype would be a valuable finding in the study of fetal growth and disease, and additional exploration of complex interactions between fetal genetic factors may help in elucidating the mechanisms underlying these associations.
